The extracellular matrix degradation markers as predictors of left ventricular systolic dysfunction among patients with STEMI
DOI:
https://doi.org/10.34287/MMT.1(48).2021.4Abstract
The purpose of the study. To determine predictor value of the extracellular matrix degradation markers relative to the occurrence of left ventricular systolic dysfunction among patients with STEMI determined.
Materials and methods. The results of the study are based on data obtained from a comprehensive survey of 162 patients with STEMI. The first group consisted of 145 patients with STEMI and left ventricular ejection fraction > 45% (median age – 59 (52–64) years); the second group consisted of 17 patients with STEMI and left ventricular ejection fraction < 45% (median age 61 (55–63) years). All persons were comparable in age, social status, and gender. The sample of patients was carried out in the period from 2015 to January 2018 on the basis of the MI «Regional medical center of cardiovascular diseases» of the Zaporizhzhia regional Council.
Results. Significantly, the level of 5816,3 (5487,7–6538,6) PG/ml of matrix metalloproteinase-9 was higher in the left ventricular ejection fraction group < 45% compared to 5129,6 (3984,6–5975,8) PG/ml in the left ventricular ejection fraction group > 45%, (p < 0,05). The level of tissue inhibitor of matrix metalloproteinase-2 among patients with left ventricular ejection fraction < 45% was 524,8 (484,6–648,7) PG/ml and was considerably higher compared to 459,7 (368,3–549,2) PG/ml in the left ventricular ejection fraction group > 45%, (p < 0,05). The largest area under the ROC curve (AUC = 0,694, 95% CI 0,617 to 0,764) among the analyzed markers of extracellular matrix degradation was tissue inhibitor of matrix metalloproteinase-2. At the distribution point > 483,7 PG/ml, the sensitivity was 76,47% and the specificity was 62,07% for left ventricular systolic dysfunction among patients with STEMI. The calculated relative risk was for matrix metalloproteinase-9 > 5247,9 PG/ml for the development of left ventricular systolic dysfunction was 7,139, 95% CI 1,686–30,218. For the level of tissue inhibitor of matrix metalloproteinase-2 > 483,7 PG/ml, the relative risk was 4,271, 95% CI 1,455–12,536 for the development of left ventricular systolic dysfunction.
Conclusions. Patients having STEMI with left ventricular ejection fraction < 45% had essentially higher levels of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2. At matrix metalloproteinase-9 > 5247.9 PG/ml level relative risk of the developing left ventricular systolic dysfunction in patients with STEMI increases by 7.139 times.
References
Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017; 389 (10065): 197–210. DOI: 10.1016/S0140-6736 (16)30677-8.
Takuma T, Koki S, Takahiro HІ et al. Impact of Late Ventricular Arrhythmias on Cardiac Mortality in Patients with Acute Myocardial Infarction. Journal of Interventional Cardiology. 2019; 2019: 1–9. DOI: 10.1155/2019/5345178.
Gershlick AH, Banning AP, Myat A et al. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? The Lancet. 2013; 382 (9892): 624–632. DOI: 10.1016/S0140-6736 (13)61454-3.
Tiu DN, Agarwal A. Left ventricular dysfunction after acute myocardial infarction – a prospective study. Journal of Advanced Medical and Dental Sciences Research. 2017; 5 (6): 36–40. DOI: 10.21276/jamdsr.2017.5.6.10.
DeLeon-Pennell KY, Meschiari CA, Jung M et al. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progr Mol Biol Trans Sci. 2017; 147: 75–100. DOI: 10.1016/bs.pmbts.2017.02.001.
Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Advances in pharmacology. 2018; 81: 241–330. DOI: 10.1016/bs.apha.2017.08.002.
Bencsik P, Sasi V, Kiss K et al. Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients. European journal of clinical investigation. 2015; 45 (7): 692–701. DOI: 10.1111/eci.12458.
Lindsey ML, Iyer RP, Jung M, DeLeon- Pennell KY, Ma Y. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. Journal of molecular and cellular cardiology. 2016; 91: 134–140. DOI: 10.1016/j.yjmcc.2015.12.018.
Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. European heart journal. 2012; 33 (20): 2551–2567. DOI: 10.1093/eurheartj/ehs184.
Thygesen K, Alpert JS, Jaffe AS et al. Fourth universal definition of myocardial infarction. European heart journal. 2018; 40 (3): 237–269. DOI: 10.1093/eurheartj/ehy462.
Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal- Cardiovascular Imaging. 2015; 16 (3): 233–271. DOI: 10.1093/ehjci/jev014.
Iyer RP, Jung M, Lindsey ML. MMP-9 signaling in the left ventricle following myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2016; 311 (1): H190–H198. DOI: 10.1152/ajpheart.00243.2016.
Fertin M, Dubois E, Belliard A et al. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. The American journal of cardiology. 2012; 110 (2): 277–283. DOI: 10.1016/j.amjcard.2012.02.069.
Cogni AL, Farah E, Minicucci MF et al. Metalloproteinases-2 and-9 predict left ventricular remodeling after myocardial infarction. Arquivos brasileiros de cardiologia. 2013; 100 (4): 315–321. DOI: 10.5935/abc.20130049.
Ding S, Liu H, Lu Q et al. Changes of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 during left ventricular remodeling in acute myocardial infarction patients after percutaneous coronary intervention. Biomedical Research. 2013; 24 (2): 179–184.
Bazyilev VV, Karnahin VA, Evtyushkin IA, et al. Svyaz remodelirovaniya levogo zheludochka i urovnya matrichnoy metalloproteinazyi-9 u bolnyih ishemicheskoy boleznyu serdtsa. Kardiologiya i serdechno-sosudistaya hirurgiya. 2018; 11 (5): 15–21.
